Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2023 | Real-world experiences with toxicity in patients treated with CAR-T cell therapy

Eleni Gavriilaki • 10 Feb 2023
CAR-T Meeting 2023
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma CAR-T

Eleni Gavriilaki, MD, PhD, G. Papanikolaou Hospital, Thessaloniki, Greece, discusses real-world data (RWD) on the toxicities observed in patients treated with various CAR-T cell therapies, and further highlights the importance of increasing awareness and obtaining RWD in this space. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

EG has received research funding and honoraria from Gilead.

More from Eleni Gavriilaki

0:58
Agents under investigation for the treatment of TA-TMA
Eleni Gavriilaki • 16 Feb 2024
1:03
Cognitive impairment in patients receiving CAR T-cell therapy
Eleni Gavriilaki • 16 Feb 2024
0:52
Long-term complications in patients with hematological malignancies post-SCT
Eleni Gavriilaki • 11 Dec 2023
1:19
The potential of caplacizumab in the treatment of aTTP
Eleni Gavriilaki • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals